Laboratory Medicine ›› 2018, Vol. 33 ›› Issue (8): 674-678.DOI: 10.3969/j.issn.1673-8640.2018.08.002
• Orginal Article • Previous Articles Next Articles
GONG Jian, LIU Fang, GAO Peng, XU Jianfeng
Received:
2018-03-09
Online:
2018-08-10
Published:
2018-09-07
CLC Number:
GONG Jian, LIU Fang, GAO Peng, XU Jianfeng. Changes of clinical laboratory determination indicators in male androgenic alopecia patients[J]. Laboratory Medicine, 2018, 33(8): 674-678.
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.shjyyx.com/EN/10.3969/j.issn.1673-8640.2018.08.002
组别 | 例数 | 年龄(岁) | T3(nmol/L) | T4(nmol/L) | FT3(pmol/L) |
---|---|---|---|---|---|
MAA组 | 430 | 65.40±0.46 | 1.58±0.21 | 80.36±14.02 | 4.40±0.43 |
正常对照组 | 617 | 65.43±0.30 | 1.58±0.23 | 82.10±13.54 | 4.34+0.43 |
P值 | 0.63 | 0.99 | 0.14 | 0.05 | |
组别 | FT4(pmol/L) | TSH(mIU/L) | TPOAb(kIU/L) | TG(μg/L) | TgAb(kIU/L) |
MAA组 | 12.78±1.35 | 1.72±1.66 | 0.23(0.12~0.53) | 8.92(4.93~13.71) | 0.95(0.71~1.81) |
正常对照组 | 12.82±1.38 | 1.88±3.04 | 0.25(0.11~0.40) | 8.39(5.02~15.29) | 0.93(0.67~1.58) |
P值 | 0.64 | 0.28 | 0.27 | 0.32 | 0.31 |
组别 | 例数 | 年龄(岁) | T3(nmol/L) | T4(nmol/L) | FT3(pmol/L) |
---|---|---|---|---|---|
MAA组 | 430 | 65.40±0.46 | 1.58±0.21 | 80.36±14.02 | 4.40±0.43 |
正常对照组 | 617 | 65.43±0.30 | 1.58±0.23 | 82.10±13.54 | 4.34+0.43 |
P值 | 0.63 | 0.99 | 0.14 | 0.05 | |
组别 | FT4(pmol/L) | TSH(mIU/L) | TPOAb(kIU/L) | TG(μg/L) | TgAb(kIU/L) |
MAA组 | 12.78±1.35 | 1.72±1.66 | 0.23(0.12~0.53) | 8.92(4.93~13.71) | 0.95(0.71~1.81) |
正常对照组 | 12.82±1.38 | 1.88±3.04 | 0.25(0.11~0.40) | 8.39(5.02~15.29) | 0.93(0.67~1.58) |
P值 | 0.64 | 0.28 | 0.27 | 0.32 | 0.31 |
组别 | 例数 | f-PSA(μg/L) | f-PSA/t-PSA比值 | AFP(ng/mL) | CYFRA 21-1(U/mL) | CA125(U/mL) | |||
---|---|---|---|---|---|---|---|---|---|
MAA组 | 430 | 0.45±0.03 | 0.31±0.02 | 2.28(1.73~3.02) | 2.00(1.43~2.76) | 5.64(1.87~6.81) | |||
正常对照组 | 617 | 0.37±0.03 | 0.24±0.02 | 2.16(1.61~2.71) | 2.15(1.82~3.16) | 4.47(1.88~5.25) | |||
P值 | <0.01 | <0.01 | 0.06 | 0.07 | 0.07 | ||||
组别 | CA199(U/mL) | CA242(U/mL) | CA50(U/mL) | CA724(U/mL) | |||||
MAA组 | 10.14(3.65~10.45) | 3.93(2.30~6.30) | 3.71(3.01~5.12) | 1.81(1.06~4.45) | |||||
正常对照组 | 9.53(3.30~13.20) | 5.14(1.95~5.35) | 3.98(3.04~5.08) | 1.64(1.03~3.05) | |||||
P值 | 0.72 | 0.23 | 0.37 | 0.10 |
组别 | 例数 | f-PSA(μg/L) | f-PSA/t-PSA比值 | AFP(ng/mL) | CYFRA 21-1(U/mL) | CA125(U/mL) | |||
---|---|---|---|---|---|---|---|---|---|
MAA组 | 430 | 0.45±0.03 | 0.31±0.02 | 2.28(1.73~3.02) | 2.00(1.43~2.76) | 5.64(1.87~6.81) | |||
正常对照组 | 617 | 0.37±0.03 | 0.24±0.02 | 2.16(1.61~2.71) | 2.15(1.82~3.16) | 4.47(1.88~5.25) | |||
P值 | <0.01 | <0.01 | 0.06 | 0.07 | 0.07 | ||||
组别 | CA199(U/mL) | CA242(U/mL) | CA50(U/mL) | CA724(U/mL) | |||||
MAA组 | 10.14(3.65~10.45) | 3.93(2.30~6.30) | 3.71(3.01~5.12) | 1.81(1.06~4.45) | |||||
正常对照组 | 9.53(3.30~13.20) | 5.14(1.95~5.35) | 3.98(3.04~5.08) | 1.64(1.03~3.05) | |||||
P值 | 0.72 | 0.23 | 0.37 | 0.10 |
组别 | 例数 | FFA(mmol/L) | TC(mmol/L) | TG(mmol/L) | HDL-C(mmol/L) | LDL-C(mmol/L) |
---|---|---|---|---|---|---|
MAA组 | 430 | 0.53±0.22 | 4.99±0.97 | 1.82±1.59 | 1.25±0.27 | 3.07±0.85 |
正常对照组 | 617 | 0.58±0.26 | 5.03±0.98 | 1.69±1.22 | 1.27±0.28 | 3.11±0.81 |
P值 | 0.30 | 0.37 | 0.09 | 0.27 | 0.44 | |
组别 | ALP(IU/L) | apo A(g/L) | apo B(g/L) | apo E(g/L) | Lp(a) (g/L) | |
MAA组 | 66.00±14.97 | 1.42±0.28 | 1.00±0.34 | 1.12±0.01 | 0.24±0.39 | |
正常对照组 | 69.00±19.08 | 1.40±0.18 | 0.98±0.22 | 0.98±0.01 | 0.21±0.18 | |
P值 | 0.036 | 0.10 | 0.22 | <0.01 | 0.61 | |
组别 | Glu(mmol/L) | TP(g/L) | PA(mg/L) | DBil(μmol/L) | TB(μmol/L) | |
MAA组 | 6.04±1.80 | 73.28±3.86 | 272.33±40.91 | 2.77±1.03 | 15.64±5.59 | |
正常对照组 | 6.22±1.45 | 72.46±4.45 | 269.73±41.87 | 2.74±1.15 | 15.29±5.82 | |
P值 | 0.07 | <0.05 | 0.21 | 0.66 | 0.34 |
组别 | 例数 | FFA(mmol/L) | TC(mmol/L) | TG(mmol/L) | HDL-C(mmol/L) | LDL-C(mmol/L) |
---|---|---|---|---|---|---|
MAA组 | 430 | 0.53±0.22 | 4.99±0.97 | 1.82±1.59 | 1.25±0.27 | 3.07±0.85 |
正常对照组 | 617 | 0.58±0.26 | 5.03±0.98 | 1.69±1.22 | 1.27±0.28 | 3.11±0.81 |
P值 | 0.30 | 0.37 | 0.09 | 0.27 | 0.44 | |
组别 | ALP(IU/L) | apo A(g/L) | apo B(g/L) | apo E(g/L) | Lp(a) (g/L) | |
MAA组 | 66.00±14.97 | 1.42±0.28 | 1.00±0.34 | 1.12±0.01 | 0.24±0.39 | |
正常对照组 | 69.00±19.08 | 1.40±0.18 | 0.98±0.22 | 0.98±0.01 | 0.21±0.18 | |
P值 | 0.036 | 0.10 | 0.22 | <0.01 | 0.61 | |
组别 | Glu(mmol/L) | TP(g/L) | PA(mg/L) | DBil(μmol/L) | TB(μmol/L) | |
MAA组 | 6.04±1.80 | 73.28±3.86 | 272.33±40.91 | 2.77±1.03 | 15.64±5.59 | |
正常对照组 | 6.22±1.45 | 72.46±4.45 | 269.73±41.87 | 2.74±1.15 | 15.29±5.82 | |
P值 | 0.07 | <0.05 | 0.21 | 0.66 | 0.34 |
组别 | 例数 | INS(μU/mL) | PGⅠ(ng/mL) | PGⅡ(ng/mL) | PGR |
---|---|---|---|---|---|
MAA组 | 430 | 10.49±0.86 | 59.16±28.83 | 13.08±6.71 | 4.70±1.14 |
正常对照组 | 617 | 7.62±0.72 | 57.54±22.22 | 12.69±6.16 | 5.03±1.18 |
P值 | <0.05 | 0.69 | 0.71 | 0.07 | |
组别 | IgA(mg/L) | IgE(mg/L) | IgG(mg/L) | IgM(mg/L) | |
MAA组 | 263.27(137.00~375.00) | 9.12(3.39~141.50) | 924.00(908.50~1 420.00) | 87.31(52.00~116.50) | |
正常对照组 | 243.47(150.00~273.75) | 13.50(12.32~163.50) | 918.18(898.50~1 277.50) | 102.42(53.25~127.00) | |
P值 | 0.51 | 0.07 | 0.57 | 0.48 |
组别 | 例数 | INS(μU/mL) | PGⅠ(ng/mL) | PGⅡ(ng/mL) | PGR |
---|---|---|---|---|---|
MAA组 | 430 | 10.49±0.86 | 59.16±28.83 | 13.08±6.71 | 4.70±1.14 |
正常对照组 | 617 | 7.62±0.72 | 57.54±22.22 | 12.69±6.16 | 5.03±1.18 |
P值 | <0.05 | 0.69 | 0.71 | 0.07 | |
组别 | IgA(mg/L) | IgE(mg/L) | IgG(mg/L) | IgM(mg/L) | |
MAA组 | 263.27(137.00~375.00) | 9.12(3.39~141.50) | 924.00(908.50~1 420.00) | 87.31(52.00~116.50) | |
正常对照组 | 243.47(150.00~273.75) | 13.50(12.32~163.50) | 918.18(898.50~1 277.50) | 102.42(53.25~127.00) | |
P值 | 0.51 | 0.07 | 0.57 | 0.48 |
组别 | 例数 | 全血黏度 | 全血还原黏度 | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
低切(3/s) | 中切(50/s) | 高切(200/s) | 低切 | 中切 | 高切 | |||||||
MAA组 | 430 | 12.09±1.77 | 7.40±0.04 | 5.71±0.59 | 17.19±1.41 | 9.85±0.35 | 6.76±0.66 | |||||
正常对照组 | 617 | 12.03±0.96 | 7.16±0.04 | 5.56±0.45 | 17.23±1.46 | 9.32±0.82 | 6.71±0.63 | |||||
P值 | 0.65 | <0.01 | 0.09 | 0.81 | 0.73 | 0.49 | ||||||
组别 | 钾(mmol/L) | 钠(mmol/L) | 氯(mmol/L) | 磷(mmol/L) | 镁(mmol/L) | HbA1c(%) | ||||||
MAA组 | 4.24±0.28 | 142.75±2.07 | 103.83±0.83 | 1.05±0.13 | 0.90±0.06 | 5.84±1.07 | ||||||
正常对照组 | 4.37±0.33 | 142.68±1.78 | 104.50±2.18 | 1.00±0.16 | 0.87±0.06 | 5.97±1.01 | ||||||
P值 | 0.13 | 0.91 | 0.31 | 0.31 | 0.15 | 0.06 |
组别 | 例数 | 全血黏度 | 全血还原黏度 | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
低切(3/s) | 中切(50/s) | 高切(200/s) | 低切 | 中切 | 高切 | |||||||
MAA组 | 430 | 12.09±1.77 | 7.40±0.04 | 5.71±0.59 | 17.19±1.41 | 9.85±0.35 | 6.76±0.66 | |||||
正常对照组 | 617 | 12.03±0.96 | 7.16±0.04 | 5.56±0.45 | 17.23±1.46 | 9.32±0.82 | 6.71±0.63 | |||||
P值 | 0.65 | <0.01 | 0.09 | 0.81 | 0.73 | 0.49 | ||||||
组别 | 钾(mmol/L) | 钠(mmol/L) | 氯(mmol/L) | 磷(mmol/L) | 镁(mmol/L) | HbA1c(%) | ||||||
MAA组 | 4.24±0.28 | 142.75±2.07 | 103.83±0.83 | 1.05±0.13 | 0.90±0.06 | 5.84±1.07 | ||||||
正常对照组 | 4.37±0.33 | 142.68±1.78 | 104.50±2.18 | 1.00±0.16 | 0.87±0.06 | 5.97±1.01 | ||||||
P值 | 0.13 | 0.91 | 0.31 | 0.31 | 0.15 | 0.06 |
[1] | HORDINSKY M,JUNQUEIRA A L.Alopecia areata update[J]. Semin Cutan Med Surg,2015,34(2):72-75. |
[2] | 赵辨. 中国临床皮肤病学[M]. 江苏:江苏科学技术出版社,2010:1185. |
[3] | HAYES V M,SEVERI G,PADILLA E J,et al.5Alpha-reductase type 2 gene variant associations with prostate cancer risk,circulating hormone levels and androgenetic alopecia[J]. Int J Cancer,2007, 120(4):776-780. |
[4] | SAWAYA M E,PRICE V H.Different levels of 5alpha-reductase typeⅠ and Ⅱ,aromatase,and androgen receptor in hair follicles of women and men with androgenetic alopecia[J]. J Invest Dermatol, 1997,109(3):296-300. |
[5] | OLSEN E A,WHITING D,BERGFELD W,et al.A multicenter,randomized,placebo-controlled,double-blind clinical trial of a novel formulation of 5% minoxidil topical foam versus placebo in the treatment of androgenetic alopecia in men[J]. J Am Acad Dermatol,2007,57(5): 767-774. |
[6] | DASTGHEIB L,SHIRAZI M,MOEZZI I,et al.Is there a relationship between androgenic alopecia and benign prostatic hyperplasia?[J]. Acta Med Iran,2015,53(1):30-32. |
[7] | WANG T L,ZHOU C,SHEN Y W,et al.Prevalence of androgenetic alopecia in China:a community-based study in six cities[J]. Br J Dermatol,2010,162(4):843-847. |
[8] | SU L H,CHEN L S,LIN S C,et al.Association of androgenetic alopecia with mortality from diabetes mellitus and heart disease[J]. JAMA Dermatol,2013,149(5):601-606. |
[9] | SHARMA K H,JINDAL A.Association between androgenetic alopecia and coronary artery disease in young male patients[J]. Int J Trichology,2014,6(1):5-7. |
[10] | 周北凡. 心血管病流行病学调查方法手册[M]. 北京:北京医科大学出版社,1997:9-66. |
[11] | ARIAS-SANTIAGO S,GUTIÉRREZ-SALMERÓN M T,BUENDÍA-EISMAN,et al. Hypertension and aldosterone levels in women with early-onset androgenetic alopecia[J]. Br J Dermatol,2010,162(4):786-789. |
[12] | LOTUFO P A,CHAE C U,AJANI U A,et al.Male pattern baldness and coronary heart disease:the Physicians' Health Study[J]. Arch Intern Med,2000,160(2):165-171. |
[13] | HU R,XU F,HAN Y,et al.Trichoscopic findings of androgenetic alopecia and their association with disease severity[J]. J Dermatol,2015,42(6):602-607. |
[14] | KARTAL D,BORLU M,CINAR S L,et al.The association of androgenetic alopecia and insulin resistance is independent of hyperandrogenemia:a case-control study[J]. Australas J Dermatol,2016,57(3):e88-e92. |
[15] | CHIU H W,CHEN M H,FANG W H,et al.Preventive effects of monascus on androgen-related diseases:androgenetic alopecia,benign prostatic hyperplasia,and prostate cancer[J]. J Agric Food Chem,2013,61(18):4379-4386. |
[16] | MULLER D C,GILES G G,SINCLAIR R,et al.Age-dependent associations between androgenetic alopecia and prostate cancer risk[J]. Cancer Epidemiol Biomarkers Prev,2013,22(2):209-215. |
[1] | CHEN Xuewei, LI Yirong. Candidate biomarkers in metabolic syndrome based on GEO database [J]. Laboratory Medicine, 2023, 38(1): 32-38. |
[2] | CHEN Liang, LI Lin, LI Xia, ZHANG Yan, WU Jiongrui, GAO Yiming. Correlation between metabolic syndrome and moderate-to-severe periodontitis complicated with psoriasis [J]. Laboratory Medicine, 2022, 37(2): 126-129. |
[3] | CHI Wenjing, DING Li, LIU Yixin, YANG Feng, LIU Tao, CONG Jianhua, GAO Zhenhui, ZHAO Hu, ZHANG Yanmei. Correlation analysis of Helicobacter pylori colonization level and metabolic syndrome in physical examination population in Shanghai [J]. Laboratory Medicine, 2022, 37(11): 1034-1038. |
[4] | ZHOU Zhongwei, JU Huixiang, JIN Hao, CHEN Hongmei, SUN Mingzhong. Relationship between alpha 2-Heremans-Schmid glycoprotein to adiponectin ratio and type 2 diabetes mellitus complicated with metabolic syndrome [J]. Laboratory Medicine, 2020, 35(5): 414-419. |
[5] | LIU Xiaoni, WANG Ying, LI Taotao, MA Xiaomin, ZHAO Huanlao. Correlation of insulin resistance index and chronic inflammation index in type 2 diabetes mellitus patients with metabolic syndrome [J]. Laboratory Medicine, 2019, 34(9): 826-830. |
[6] | ZHU Wenkui, XU Qi, CHEN Jin. Correlations of serum calcium and free fatty acid with metabolic syndrome among elders in community [J]. Laboratory Medicine, 2018, 33(5): 407-410. |
[7] | JI Hongbing, JU Huixiang, SUN Mingzhong, CHEN Hongmei, HAN Yuqing, ZHOU Zhongwei. Correlation of the changes of serum alpha2-Heremans-Schmid glycoprotein levels with metabolic syndrome [J]. Laboratory Medicine, 2017, 32(8): 677-680. |
[8] | CHEN Xiaoqin, REN Jing. Correlations of serum free fatty acid and insulin resistance with metabolic syndrome [J]. Laboratory Medicine, 2016, 31(7): 553-558. |
[9] | XIONG Yongrui, MAO Xiaohong, ZHANG Juanwen, ZHAO Ying, WU Jianping. Clinical significance of serum pancreatic lipase in nonalcoholic fatty liver disease [J]. Laboratory Medicine, 2016, 31(3): 180-184. |
[10] | ZHANG Benhong, ZHANG Fei, CHEN Baode, XU Songxiao, CHENG Haien. The influence of metabolic syndrome and its risk components on serum prostate-specific antigen level [J]. , 2014, 29(9): 940-944. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||